Concord Healthcare Announces Official Release of the Proton Therapy Large Model
Concord Healthcare Group (NYSE: CCM), a subsidiary of Concord Medical Services Holdings, has officially launched China's first large language model (LLM) specialized in proton therapy. The model has been successfully deployed at Guangzhou Concord Cancer Hospital, where it has already demonstrated success in multiple patient treatment cases.
The LLM integrates nearly 10,000 high-quality radiotherapy cases, incorporating multimodal medical data, Proton China data, and professional journal literature. The technology has shown promising results with precise treatment capabilities, significant efficacy, and reduced side effects. This development builds on Concord Healthcare's extensive experience in tumor diagnosis and treatment technology.
Concord Healthcare Group (NYSE: CCM), una controllata di Concord Medical Services Holdings, ha lanciato ufficialmente il primo modello di linguaggio di grandi dimensioni (LLM) in Cina specializzato nella terapia protonica. Il modello è stato implementato con successo presso il Guangzhou Concord Cancer Hospital, dove ha già mostrato risultati positivi in diversi casi di trattamento dei pazienti.
Il LLM integra quasi 10.000 casi di radioterapia di alta qualità, includendo dati medici multimodali, dati Proton China e letteratura professionale. La tecnologia ha dimostrato risultati promettenti con capacità di trattamento precise, efficacia significativa e riduzione degli effetti collaterali. Questo sviluppo si basa sull'ampia esperienza di Concord Healthcare nella diagnosi e nel trattamento dei tumori.
Concord Healthcare Group (NYSE: CCM), una subsidiaria de Concord Medical Services Holdings, ha lanzado oficialmente el primer modelo de lenguaje grande (LLM) especializado en terapia de protones en China. El modelo se ha implementado con éxito en el Hospital de Cáncer Concord de Guangzhou, donde ya ha demostrado éxito en múltiples casos de tratamiento de pacientes.
El LLM integra cerca de 10,000 casos de radioterapia de alta calidad, incorporando datos médicos multimodales, datos de Proton China y literatura profesional. La tecnología ha mostrado resultados prometedores con capacidades de tratamiento precisas, eficacia significativa y reducción de efectos secundarios. Este desarrollo se basa en la amplia experiencia de Concord Healthcare en el diagnóstico y tratamiento de tumores.
Concord Healthcare Group(NYSE: CCM)는 Concord Medical Services Holdings의 자회사로서 중국 최초의 양성자 치료에 특화된 대형 언어 모델(LLM)을 공식 출시했습니다. 이 모델은 광저우 콘코드 암 병원에 성공적으로 도입되어 여러 환자 치료 사례에서 이미 성과를 입증했습니다.
이 LLM은 거의 10,000건의 고품질 방사선 치료 사례를 통합하며, 다중 모달 의료 데이터, Proton China 데이터, 전문 학술 문헌을 포함합니다. 이 기술은 정밀한 치료 능력, 뛰어난 효능, 부작용 감소라는 유망한 결과를 보여주고 있습니다. 이번 개발은 Concord Healthcare가 암 진단 및 치료 기술에서 쌓아온 풍부한 경험을 바탕으로 이루어졌습니다.
Concord Healthcare Group (NYSE : CCM), une filiale de Concord Medical Services Holdings, a officiellement lancé le premier modèle de langage de grande taille (LLM) spécialisé dans la protonthérapie en Chine. Le modèle a été déployé avec succès au Guangzhou Concord Cancer Hospital, où il a déjà démontré son efficacité dans plusieurs cas de traitement de patients.
Le LLM intègre près de 10 000 cas de radiothérapie de haute qualité, en incorporant des données médicales multimodales, des données de Proton China et de la littérature professionnelle. Cette technologie a montré des résultats prometteurs avec des capacités de traitement précises, une efficacité significative et une réduction des effets secondaires. Ce développement s’appuie sur l’expérience approfondie de Concord Healthcare dans le diagnostic et le traitement des tumeurs.
Concord Healthcare Group (NYSE: CCM), eine Tochtergesellschaft von Concord Medical Services Holdings, hat offiziell das erste große Sprachmodell (LLM) Chinas vorgestellt, das auf die Protonentherapie spezialisiert ist. Das Modell wurde erfolgreich im Guangzhou Concord Cancer Hospital eingesetzt und hat bereits in mehreren Patientenbehandlungsfällen Erfolge gezeigt.
Das LLM integriert nahezu 10.000 hochwertige Strahlentherapiefälle und umfasst multimodale medizinische Daten, Proton China-Daten sowie Fachliteratur. Die Technologie zeigt vielversprechende Ergebnisse mit präzisen Behandlungsmöglichkeiten, signifikanter Wirksamkeit und reduzierten Nebenwirkungen. Diese Entwicklung baut auf der umfangreichen Erfahrung von Concord Healthcare in der Tumordiagnostik und -behandlung auf.
- First proton therapy LLM in China, establishing technological leadership
- Successfully deployed and validated with multiple patient cases
- Integration of 10,000 high-quality radiotherapy cases enhancing model accuracy
- Demonstrated positive clinical outcomes with reduced side effects
- None.
Concord Healthcare's proton LLM is the first LLM focusing on proton therapy in
The Company previously announced the listing of Concord Healthcare's H shares on the HKSE on January 9, 2024. The information related to Concord Healthcare's Transactions on the HKSE is accessible through the HKSE's website at www.hkexnews.hk.
About Concord Medical
Concord Medical Services Holdings Limited is a healthcare provider featuring a full cycle of premium oncology services including cancer diagnosis, treatment, education and prevention. The Company focuses on providing multidisciplinary cancer care in all aspects of oncology healthcare services in its cancer hospitals and equipping them with technologically advanced equipment such as the state-of-the-art proton therapy system. The Company is striving to improve the quality and accessibility of cancer care through its network of self-owned cancer hospitals and clinics as well as partnered hospitals across China. For more information, please see http://ir.ccm.cn.
About Concord Healthcare
Concord Healthcare is an oncology healthcare provider in
Safe Harbor Statement
This announcement contains forward-looking statements. These forward-looking statements can be identified by words or phrases such as "will," "expects," "anticipates," "future," "intends," "plans," "believes," "estimates" and similar expressions. Forward-looking statements are inherently subject to uncertainties and contingencies beyond the Company's control and based upon premises with respect to future business decisions, which are subject to change. A number of important factors could cause actual results to differ materially from those contained in any forward-looking statement. The Company does not undertake any obligation to update any forward-looking statement, except as required under applicable law.
View original content:https://www.prnewswire.com/news-releases/concord-healthcare-announces-official-release-of-the-proton-therapy-large-model-302468669.html
SOURCE Concord Medical Services Holdings Limited
FAQ
What is the new proton therapy LLM launched by Concord Healthcare (NYSE: CCM)?
Where has Concord Healthcare (CCM) deployed its new proton therapy LLM?
What are the main benefits of Concord Healthcare's proton therapy LLM?
How many radiotherapy cases does Concord Healthcare's proton LLM integrate?
